Close

A uniCAR [Anti-CD16 (FCGR3A) 158(V/V)(FCGR3A)-CD3TM/ CD3ζ], with a mAb-based CAR Adaptor [Anti-CD20 (Rituximab)], a Switchable CAR System (CAR-ZP8486)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Creative Biolabs has developed a switchable CAR (sCAR) T cell platform that allows dose-titratable control over CAR T cell activity by using adaptor-based switches. Our switchable CAR product aims to further evolve CAR-T cell therapy based on combinations of so-called universal or modular CAR-(uniCAR/modCAR-) T cells, and their respective adaptor molecules (CAR-adaptors), which mediate the crosslinking between target and effector cells. Thus, the universal or modCARs describe chimeric receptors that do not directly recognize the target antigen, but instead make contact to adaptor molecules (CAR-adaptors), that in turn bind to the target antigen. Contrary to conventional CAR-T cells, where the immunological synapse is established by direct interaction of CAR and membrane-bound target, modCAR-T cells provide a highly flexible and customizable development of the CAR-T cell concept and offer an additional possibility to control T cell activity.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

UniCAR

  • scFv Target
  • CD16
  • CAR Construction
  • anti-CD16 (FCGR3A) 158(V/V)(FCGR3A)-CD3TM/ CD3ζ
  • Discription of Signaling Cassetes
  • CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.
  • Vector Name
  • pCDCAR1
  • Vector length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Targeting Diseases
  • Mature B cell neoplasms

CAR Adaptor

  • Common Name
  • MS4A1
  • Adaptor Type
  • mAb-based
  • Antibody Clone
  • Rituximab
  • CAR Adaptor Tag
  • IgG-biotinylated

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System

Customer Reviews and Q&As

There are currently no customer reviews or questions for A uniCAR [Anti-CD16 (FCGR3A) 158(V/V)(FCGR3A)-CD3TM/ CD3ζ], with a mAb-based CAR Adaptor [Anti-CD20 (Rituximab)], a Switchable CAR System (CAR-ZP8486). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.